Daily briefing

Medicare roadmap says AI could deliver much of the annual wellness visit

Nov 16, 2026

Illustration: a stone pathway leads across a grassy lawn to a lit cabin doorway.

A federal roadmap posted by CMS says artificial intelligence tools could deliver many components of the Medicare Annual Wellness Visit and lead care inside Medicare payment models.

The document, written for HHS, CMS and the Food and Drug Administration, also floats extending an outcome-based payment model to primary care and federal device rules that could preempt differing state requirements, while stating that it does not mandate adoption. Apple on Sunday opened a health chatbot study to as many as 200,000 iPhone users, with answers supplied by OpenEvidence.

In JAMA, tirzepatide lowered BMI 18.5% in adolescents with obesity over 72 weeks, and the FDA turned down the lung cancer drug ivonescimab because its trial showed no statistically significant overall survival benefit.

  • WatchRegulation Nov 13, 2026

    The roadmap sets no deadlines; CMS says it anticipates extending its ACCESS outcome-payment model to primary care.

    Primary carePractices
    "Many components of the Medicare Annual Wellness visit could potentially be delivered via clinical SI tools," according to A Clinical Super Intelligence Roadmap, a federal framework for HHS, CMS and the Food and Drug Administration that CMS has posted on its website. The document uses the term Super Intelligence, or SI, noting that the HHS strategy once titled for AI now carries the SI label, and it says CMS anticipates creating structures for SI-led solutions to take part in Innovation Center models, with its capitated and total-cost-of-care models such as LEAD and AHEAD as a pathway for payment. CMS also anticipates extending the ACCESS model, which pays for clinical results in chronic conditions rather than activities, to primary care, and aims to foster SI-led options in the Marketplaces and Medicare Advantage. On the FDA side, it describes a potential competency-based premarket approach for certain SI-enabled devices, regulatory actions that "may trigger express preemption" of differing state or local requirements, and state sandboxes for areas only states regulate. The roadmap says it "does not mandate SI adoption," sets no deadlines and names no comment period; its web page was last updated Nov. 13.
  • FYIDeployment Nov 15, 2026
    Primary care
    Apple on Nov. 15 opened the Apple Health AI Usage Study, a virtual research study and app that lets up to 200,000 U.S. adults 21 and older ask everyday health questions and get answers in plainer language, each linked to peer-reviewed clinical citations. OpenEvidence, a clinical AI platform used by health care professionals, supplies the medical AI, and participants may share HealthKit data such as resting heart rate, sleep and lab results; the study also tests whether the tool helps people prepare for doctor visits, Apple said. The app is not meant to diagnose or treat any condition, and guardrails try to detect certain concerning questions and suggest contacting a provider, according to Apple, which said study data will not be used to train AI models. Enrollment requires an iPhone 15 Pro or later, according to Apple, and the study is planned to run more than 12 months, TechCrunch reported; OpenEvidence deletes query and response data after 24 hours, according to the report. Apple's announcement does not say when results will be published. Correction (Nov. 16): This item has been corrected. An earlier version said the study was named the Apple Health AI Study and attributed the iPhone 15 Pro requirement to TechCrunch; Apple names it the Apple Health AI Usage Study and states the iPhone 15 Pro or later requirement, while TechCrunch reported iPhone 15 or later.
  • FYIEvidence Nov 15, 2026
    PediatricsPrimary care
    Once-weekly tirzepatide reduced body mass index 18.5% at 72 weeks in adolescents 12 to 17 with obesity, or overweight with at least one obesity-related complication, while BMI rose 0.5% on placebo, in the phase 3 SURMOUNT-ADOLESCENTS trial published Nov. 15 in JAMA. The double-blind trial randomized 160 participants 2:1 at 31 sites in six countries, including the U.S., to tirzepatide escalated to a maximum tolerated dose of 5, 10 or 15 mg or placebo, both with a healthy lifestyle intervention; mean baseline BMI was 38.6 and mean age 14.6. The estimated treatment difference was 19.0 percentage points (95% CI, 14.1 to 23.9), all 10 key secondary end points favored tirzepatide, and 79.6% of treated participants reached a BMI reduction of at least 5%, against 28.5% on placebo. Gastrointestinal events, mostly mild to moderate, were the most common adverse events, the authors reported. Eli Lilly, which makes tirzepatide, employs several of the authors.
    Sources: JAMA (DOI), PubMed
  • FYIRegulation Nov 15, 2026
    The Food and Drug Administration declined to approve ivonescimab, a PD-1 and VEGF bispecific antibody, with platinum chemotherapy for advanced EGFR-mutated nonsquamous non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy, Summit Therapeutics said Nov. 15. In the phase 3 HARMONi trial the combination met its progression-free survival end point, but overall survival showed a positive trend that was not statistically significant, and the agency found that a progression-free survival benefit without a significant overall survival improvement does not support a positive benefit-risk profile, according to the company. Summit said a post hoc analysis with longer follow-up showed an overall survival hazard ratio of 0.76 in the full, Asian and Western populations. The company said it will continue phase 3 trials, including first-line studies in non-small cell lung cancer, and did not say whether it will resubmit the application.

Latest news

  1. Medicare proposes requiring clinicians who bill Advantage plans to enroll in traditional Medicare and to report changes within 30 days
  2. Physicians' accuracy fell along with a failing AI's, and only one in eight noticed the tool breaking down, a randomized study finds
  3. Semaglutide lowered BMI 13.5% in children 6 to 11 with obesity, against a 2.7% rise on placebo, in a 68-week phase 3 trial

See all the latest news